Skip to main content

Anthem Biosciences Limited (NSE:ANTHEM)

India flag India · Delayed Price · Currency is INR
774.30
+4.55 (0.59%)
Apr 28, 2026, 3:30 PM IST
Market Cap 434.85B
Revenue (ttm) 20.02B
Net Income (ttm) 4.85B
Shares Out 561.61M
EPS (ttm) 8.58
PE Ratio 90.28
Forward PE 65.09
Dividend n/a
Ex-Dividend Date n/a
Volume 317,916
Average Volume 418,701
Open 775.05
Previous Close 769.75
Day's Range 756.95 - 785.90
52-Week Range 579.15 - 873.50
Beta n/a
RSI 69.80
Earnings Date Jun 24, 2026

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 1,825
Stock Exchange National Stock Exchange of India
Ticker Symbol ANTHEM
Full Company Profile

Financial Performance

In fiscal year 2025, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.

Financial Statements

News

Anthem Biosciences Transcript: Q3 25/26

Nine-month revenue grew to INR 1,513 crore with strong EBITDA margins above 41%. Management expects mid-teen revenue growth and EBITDA/PAT margins above 20% for FY 2026, supported by robust demand, new product approvals, and capacity expansions.

2 months ago - Transcripts

Anthem Biosciences Transcript: Q2 25/26

Revenue and EBITDA grew strongly in H1 FY2026, driven by CRDMO, with margins at 41.4%. Four new commercial molecules were added, capacity expansions are on track, and management expects continued growth and robust margins for the year.

6 months ago - Transcripts

Anthem Biosciences Transcript: Q1 25/26

Q1 FY 2026 saw 60% year-on-year revenue growth to INR 540 crore, driven by strong CRDMO performance and higher commercial molecule volumes. EBITDA margin was 38%, with steady outlook and ongoing capacity expansions funded by robust net cash.

9 months ago - Transcripts